Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.83 |
| ▸ | CNR1 | P21554 | 6/20 | 0.78 |
| ▸ | PPARA | Q07869 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31478247 | 1.00 | CNR2 (0.83) | CNR2CNR1PPARA | |
| SCHEMBL4911796 | 0.90 | CNR2 (0.81) | CNR2CNR1 | |
| SCHEMBL4460349 | 0.89 | CNR2 (0.77) | CNR2CNR1PPARA | |
| SCHEMBL2734336 | 0.88 | CNR2 (0.83) | CNR2CNR1PPARA | |
| SCHEMBL16197644 | 0.88 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL924108 | 0.87 | CNR2 (0.77) | CNR2CNR1 | |
| SCHEMBL3130177 | 0.87 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL924033 | 0.87 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL30571219 | 0.87 | CNR2 (0.76) | CNR2CNR1PPARA | |
| SCHEMBL4480064 | 0.87 | CNR2 (0.77) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632852-B2 | (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20080039510-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | US | disclosed |
| EP-1853595-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087480-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039510-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | DHFR, DPYD, THPO | CNR2 933/4885CNR1 767/4885PPARA 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.